Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-term glioblastoma multiforme survivors: a population-based study

J N Scott1, N B Rewcastle, P M Brasher

  • 1Department of Clinical Neurosciences, University of Calgary.

The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques
|August 26, 1998
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-effectiveness analysis of health tapestry, a complex primary care program for older adults: a post-hoc analysis.

BMC primary care·2024
Same author

The Experts Speak: Challenges in Banking Brain Tissue for Research.

Biopreservation and biobanking·2024
Same author

Clinical safety of intracranial EEG electrodes in MRI at 1.5 T and 3 T: a single-center experience and literature review.

Neuroradiology·2021
Same author

Author response to: Comment on: Novel chyme reinfusion device for gastrointestinal fistulas and stomas: feasibility study.

The British journal of surgery·2020
Same author

Novel chyme reinfusion device for gastrointestinal fistulas and stomas: feasibility study.

The British journal of surgery·2020
Same author

Engineering molecularly imprinted polymers (MIPs) for the selective extraction and quantification of the novel psychoactive substance (NPS) methoxphenidine and its regioisomers.

The Analyst·2018

Long-term glioblastoma multiforme survivors (LTGBMS) are rare, occurring in only 1.8% of patients. Younger age, higher performance status, and slower tumor proliferation characterize these rare glioblastoma survivors.

Area of Science:

  • Neuro-oncology
  • Cancer epidemiology
  • Clinical neurology

Background:

  • Long-term glioblastoma multiforme survivors (LTGBMS) are rare, with their frequency and predictive factors largely unknown.
  • Understanding factors contributing to long-term survival in glioblastoma (GBM) is crucial for improving patient outcomes.

Purpose of the Study:

  • To determine the population-based frequency of LTGBMS.
  • To identify patient, treatment, and tumor characteristics that predict long-term survival in glioblastoma patients.

Main Methods:

  • Utilized the Alberta Cancer Registry to identify GBM cases diagnosed between 1975-1991.
  • Reviewed patient charts and re-examined histology by a blinded neuropathologist.
  • Defined LTGBMS as survival >= 3 years and compared them to matched controls.

Related Experiment Videos

Main Results:

  • Identified 279 GBM cases; 1.8% (5 patients) were LTGBMS (survival 3.2-15.8 years).
  • LTGBMS were significantly younger (avg. 45 vs 59 years) and had higher Karnofsky Performance Status (KPS) at diagnosis.
  • LTGBMS tumors showed lower mitotic counts and a reduced Ki-67 proliferative index; radiation-induced dementia was common.

Conclusions:

  • Glioblastoma multiforme carries a dismal prognosis with a low rate of long-term survival (1.8%).
  • Younger age, higher KPS, and less rapid tumor proliferation are associated with long-term glioblastoma survival.
  • Long-term survival in GBM survivors is often associated with severe treatment-induced dementia.